Sumitomo Mitsui Ds Asset Management Company, LTD Bei Gene, Ltd. Transaction History

Sumitomo Mitsui Ds Asset Management Company, LTD

$9.15 Billion
Q3 2024

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 19, 2022	SELL	$146.52 - $269.56 $113,992 - $209,717	-778 Closed	0 $0
Q4 2021 Jan 20, 2022	BUY	$248.56 - $389.34 $40,018 - $62,683	161 Added 26.09%	778 $210,000
Q2 2021 Jul 19, 2021	BUY	$292.75 - $367.01 $180,626 - $226,445	617 New	617 $211,000
Q4 2020 Feb 02, 2021	SELL	$221.31 - $316.61 $497,504 - $711,739	-2,248 Closed	0 $0
Q3 2020 Oct 29, 2020	BUY	$189.18 - $286.44 $7,378 - $11,171	39 Added 1.77%	2,248 $643,000
Q2 2020 Aug 12, 2020	SELL	$123.9 - $195.41 $33,824 - $53,346	-273 Reduced 11.0%	2,209 $416,000
Q1 2020 Apr 21, 2020	BUY	$121.84 - $173.19 $46,786 - $66,504	384 Added 18.3%	2,482 $305,000
Q4 2019 Jan 24, 2020	BUY	$115.78 - $208.34 $578 - $1,041	5 Added 0.24%	2,098 $347,000
Q3 2019 Oct 16, 2019	BUY	$120.61 - $148.29 $18,694 - $22,984	155 Added 8.0%	2,093 $256,000
Q2 2019 Aug 13, 2019	SELL	$113.99 - $146.86 $56,425 - $72,695	-495 Reduced 20.35%	1,938 $240,000
Q1 2019 May 07, 2019	BUY	$122.82 - $151.83 $49,373 - $61,035	402 Added 19.79%	2,433 $321,000
Q4 2018 Jan 25, 2019	BUY	$107.01 - $175.15 $217,337 - $355,729	2,031 New	2,031 $284,000

Others Institutions Holding BGNE

# of Institutions

252

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

Baker Bros. Advisors LP New York, NY

10.6M
Shares

$1.89 Billion
25.41% of portfolio
Capital International Investors Los Angeles, CA

6.43M
Shares

$1.15 Billion
0.29% of portfolio
Hhlr Advisors, Ltd. Grand Cayman, E9

5.18M
Shares

$927 Million
26.65% of portfolio
Primecap Management CO Pasadena, CA

4.97M
Shares

$891 Million
0.84% of portfolio
Baillie Gifford & CO

3.71M
Shares

$664 Million
0.64% of portfolio

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sumitomo Mitsui Ds Asset Management Company, LTD, based on Form 13F filings with the SEC.

News

Stay updated on Sumitomo Mitsui Ds Asset Management Company, LTD with notifications on news.

Account